Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab

Ítems similars

• Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
  per: Hu, Shi, et al.
  Publicat: (2013)
• Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.
  per: Hu, Shi, et al.
  Publicat: (2014)
• Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
  per: An, Qing, et al.
  Publicat: (2019)
• Structural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding site
  per: Xia, Tian, et al.
  Publicat: (2014)
• Macrocyclic θ-defensins suppress tumor necrosis factor-α (TNF-α) shedding by inhibition of TNF-α–converting enzyme
  per: Schaal, Justin B., et al.
  Publicat: (2018)